Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price […]
Preclinical study shows Adicet’s Allogeneic Gamma Delta T Cell Platform may be a Promising Approach for Prostate Cancer ...
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and...
/PRNewswire/ -- The "Allogeneic CAR Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering. The global allogeneic chimeric...
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on September 29,...